PROCEPT BioRobotics Corporation Announces Pricing of Offering of Common Stock

Group 1 - PROCEPT BioRobotics Corporation announced a public offering of 1,923,076 shares of common stock at a price of $91.00 per share, aiming for gross proceeds of approximately$175 million [1] - A selling stockholder has granted underwriters a 30-day option to purchase an additional 288,461 shares at the public offering price [1] - The offering is expected to close on or about October 31, 2024, subject to customary closing conditions [1] Group 2 - BofA Securities, Piper Sandler, and Morgan Stanley are acting as joint book-running managers for the offering [2] - The securities are being offered under an effective shelf registration statement filed with the SEC on August 1, 2023 [2] Group 3 - PROCEPT BioRobotics focuses on developing transformative solutions in urology, including the AQUABEAM® and HYDROS™ Robotic Systems [5] - The HYDROS Robotic System is noted as the only AI-powered robotic technology delivering Aquablation therapy, which is designed for effective treatment of lower urinary tract symptoms due to BPH [5] - BPH affects approximately 40 million men in the United States, highlighting the market potential for PROCEPT BioRobotics' solutions [5]